Vogt Frederick G.'s Insider Trades & SAST Disclosures
Vogt Frederick G.'s most recent trade in Iovance Biotherapeutics Inc was a trade of 187,500 Restricted Stock Units done . Disclosure was reported to the exchange on March 5, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Vogt Frederick G..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 187,500 | 187,500 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 223,943 | 445,059 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 213,525 | 333,350 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.04 per share. | 03 Mar 2025 | 95,413 | 349,646 (0%) | 0% | 4.0 | 385,469 | Common Stock |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 10,418 | 41,669 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2025 | 20,835 | 0 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2025 | 20,835 | 231,071 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.89 per share. | 14 Jan 2025 | 9,955 | 221,116 (0%) | 0% | 5.9 | 58,635 | Common Stock |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 10,417 | 214,662 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 10,417 | 52,087 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.07 per share. | 02 Dec 2024 | 4,426 | 210,236 (0%) | 0% | 9.1 | 40,144 | Common Stock |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2024 | 20,834 | 213,096 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2024 | 20,834 | 20,835 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.77 per share. | 14 Oct 2024 | 8,851 | 204,245 (0%) | 0% | 9.8 | 86,474 | Common Stock |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 46,875 | 46,875 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 46,875 | 212,175 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.85 per share. | 03 Sep 2024 | 19,913 | 192,262 (0%) | 0% | 10.8 | 216,056 | Common Stock |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 10,417 | 169,726 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 10,417 | 62,504 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.85 per share. | 03 Sep 2024 | 4,426 | 165,300 (0%) | 0% | 10.8 | 48,022 | Common Stock |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 20,835 | 41,669 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 20,835 | 168,160 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.68 per share. | 15 Jul 2024 | 8,851 | 159,309 (0%) | 0% | 8.7 | 76,827 | Common Stock |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 10,417 | 72,921 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 10,417 | 151,751 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.37 per share. | 03 Jun 2024 | 4,426 | 147,325 (0%) | 0% | 8.4 | 37,046 | Common Stock |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 20,834 | 62,504 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 20,834 | 150,185 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.89 per share. | 15 Apr 2024 | 8,851 | 141,334 (0%) | 0% | 11.9 | 105,238 | Common Stock |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 41,662 | 83,338 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 41,662 | 140,800 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.96 per share. | 04 Mar 2024 | 11,449 | 129,351 (0%) | 0% | 17.0 | 194,175 | Common Stock |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 500,000 | 500,000 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 93,750 | 93,750 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Vogt Frederick G. | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 20,834 | 83,338 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | G. Frederick Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 20,834 | 105,668 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Frederick Vogt G. | Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.37 per share. | 16 Jan 2024 | 6,530 | 99,138 (0%) | 0% | 8.4 | 54,656 | Common Stock |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jul 2023 | 20,834 | 125,007 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jul 2023 | 20,834 | 81,701 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.76 per share. | 14 Jul 2023 | 8,851 | 72,850 (0%) | 0% | 7.8 | 68,684 | Common Stock |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2023 | 20,834 | 69,718 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2023 | 20,834 | 145,841 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.64 per share. | 14 Apr 2023 | 8,851 | 60,867 (0%) | 0% | 5.6 | 49,920 | Common Stock |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 500,000 | 500,000 | - | - | Stock Option (right to buy) | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 125,000 | 125,000 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 83,325 | 166,675 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 83,325 | 85,325 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.43 per share. | 17 Jan 2023 | 36,441 | 48,884 (0%) | 0% | 6.4 | 234,316 | Common Stock |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Purchase of securities on an exchange or from another person at price $ 5.98 per share. | 28 Nov 2022 | 1,000 | 2,000 (0%) | 0% | 6.0 | 5,980 | Common Stock |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Purchase of securities on an exchange or from another person at price $ 6.44 per share. | 01 Jun 2022 | 1,000 | 1,000 (0%) | 0% | 6.4 | 6,440 | Common Stock |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 250,000 | 250,000 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Interim CEO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 73,900 | 73,900 | - | - | Stock Option (right to buy) | |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 175,000 | 175,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges